Risk for PML in Multiple Sclerosis Predicted With Anti-JCV Antibody Index
While an efficacious treatment for relapsing MS, natalizumab is associated with risk of developing progressive multifocal leukoencephalopathy.
Among pediatric patients with relapsing multiple sclerosis, fingolimod is associated with a lower rate of relapse but a higher rate of serious adverse events.
In patients with progressive multiple sclerosis, slower progression of brain atrophy was seen with ibudilast versus placebo.
Following adjustment for MS disease course, the genome-wide analysis identified an association between chromosome 1q32.2 and IFN-β-induced liver injury.